This study demonstrated that daily oral treatment with sotagliflozin markedly upregulated antioxidant markers such as SIRT1 and Nrf2, attenuated TNF‐α, and reduced apoptotic and fibrogenic markers, thereby protecting against TAA‐induced liver fibrosis. Here, TNF is linked to Hepatic fibrosis.